Prescription drugs
Prescription drugs
We help navigate pharmacy benefit challenges
Milliman prescription drugs solutions
PBM contracting and management
Pharmacy plan design
Medicare Part D
Milliman prescription drugs insight
The expanding presence of the 340B Drug Pricing Program and implications of CMS's proposed CY 2027 OPPS rule
A proposed change to OPPS payments for 340B drugs could have material financial effects on non-340B hospitals, Medicare Advantage plans, and beneficiaries.
The oncology drug landscape: Spend trends, market dynamics, and the road to 2030
We examine the current state of oncology drug spending by healthcare market segment, plus the evolving drug mix, regulatory environment, and pipeline developments.
Maximum Fair Price in Medicare Part D: An inflection point for life sciences manufacturers to evaluate pharmacy reimbursement dynamics
With Medicare Part D, manufacturers that understand Maximum Fair Price and pharmacy reimbursement dynamics will be better prepared.
Why PBM audits matter
We describe how employer-sponsored health plans can use audits of their pharmacy benefit managers to identify operational and performance issues and help control drug cost expenditures.
GLP-1 medications in the United States
We provide a practical overview of the current environment for weight-loss drugs, exploring coverage obligations, utilization management strategies, and cost dynamics.
8 key ways patient cost sharing impacts life science companies
We explain key concepts and discuss several ways cost-sharing dynamics can influence decision making for life science companies.
‘Unlinking’ from the past: Measuring the potential impact from 2027 Part C and D risk adjustment model changes on Medicare Advantage Organizations
Understand how CMS's 2027 proposed risk adjustment changes could reshape Medicare Advantage reimbursement outcomes.
Milliman MedIntel Part D trend insights Q4 2025
As Medicare drug costs rise, we highlight some trends among the key populations and by product.
Approaches to lower Medicare Part D out-of-pocket costs for beneficiaries with limited income
With the sunset of two Medicare demonstration programs, states and Part D plans need to evaluate other strategies to lower cost sharing for affected individuals.
Pharmacy Briefing - March 2026
We highlight the latest pharmacy industry news, trends, and insights.
Milliman prescription drug products
Milliman Payer Network Check
MyRxConsultant
IntelliScript
Medicare Suggest
Milliman Specialty Pharmacy Insights
Milliman Price Transparency Solutions for Payers and Providers
